gms | German Medical Science

83. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

16.05. - 20.05.2012, Mainz

Clinical efficacy of subcutaneous and sublingual immunotherapy in mite-sensitized patients with allergic rhinitis

Meeting Abstract

Suche in Medline nach

  • corresponding author Lei Cheng - Nanjing Medical University, The First Affiliated Hospital, Nanjing, China
  • Luping Zhu - Nanjing Medical University, The First Affiliated Hospital, Nanjing, China
  • Qilei Tao - Nanjing Medical University, The First Affiliated Hospital, Nanjing, China
  • Ruoxi Chen - Nanjing Medical University, The First Affiliated Hospital, Nanjing, China
  • Min Yin - Nanjing Medical University, The First Affiliated Hospital, Nanjing, China

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. 83. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. Mainz, 16.-20.05.2012. Düsseldorf: German Medical Science GMS Publishing House; 2012. Doc12hnod051

doi: 10.3205/12hnod051, urn:nbn:de:0183-12hnod0510

Veröffentlicht: 4. April 2012

© 2012 Cheng et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Introduction: To investigate the clinical efficacy of subcutaneous (SCIT) and sublingual (SLIT) immunotherapy with standardized house dust mite (HDM) extract for persistent allergic rhinitis (PER).

Methods: 98 patients with moderate/severe PER caused by HDM were enrolled in this study, who completed SCIT (Alutard SQ, ALK-Abelló, Denmark) or SLIT (Chanllergen-Df drops, Wolwo Pharma, China) regimen for 2 years. All subjects were divided into two groups: SCIT group (40 patients aged 7-57 years), and SLIT group (58 patients aged 6-50 years). Patients evaluated nasal symptoms (sneezing, rhinorrhea, nasal obstruction and nasal itching) using a 4-point scale as well as 10cm-visual analogue scale (VAS). Efficacy of SCIT and SLIT was assessed as the mean change from baseline in nasal symptom scores after 2-year course of immunotherapy, and their comparison was also conducted.

Results: Both SCIT and SLIT significantly reduced the individual symptom score of sneezing, rhinorrhea, nasal obstruction and nasal itching, and the total nasal symptom scores after 2-year treatment when compared with the baseline (all P<0.05). There was no significant difference in decreased mean score of the individual and total nasal symptoms (4-point scale) between SCIT and SLIT groups (all P>0.05). However, a significant reduction of VAS score of nasal obstruction was found in SCIT group after 2-year treatment, compared with SLIT group (P=0.032). There was no significant difference in decreased VAS score of three other nasal symptoms as well as global rhinitis severity between two groups (all P>0.05).

Conclusions: Both SCIT and SLIT demonstrated clinical improvement in moderate/severe PER patients sensitized to HDM after two years treatment.

Supported by: The Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD 2010-2013), and the Health Promotion Project (XK200719, RC2007065 and RC2011071) of Jiangsu Province, the People's Republic of China.